Skip to content

Evolus EOLS Long-term portion of contingent royalty obligation payable to Evolus Founders

Long-term portion of contingent royalty obligation payable to Evolus Founders at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$407.18M-12.7%
Omeros logo
OmerosOMER
$141.93M-25.3%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$121.63M+0.1%
Ardelyx logo
ArdelyxARDX
$25.86M-2.5%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$26.91M+24.8%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$229.11M+20.4%

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept eols:ContingentRoyaltyObligationPayableToRelatedPartyNoncurrent.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's long-term portion of contingent royalty obligation payable to evolus founders.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's long-term portion of contingent royalty obligation payable to evolus founders?
Evolus (EOLS) reported long-term portion of contingent royalty obligation payable to evolus founders of $17.51M in Q1 2026.
What does long-term portion of contingent royalty obligation payable to evolus founders mean?
This represents the long-term portion of royalty obligations payable to founders or related parties that are due beyond the next fiscal year. It reflects the long-term financial commitment of the company to compensate stakeholders based on the ongoing commercial performance of its products. This metric is critical for evaluating the long-term impact of founder-related royalty structures on future profitability and capital allocation.